TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2876574

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1 (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.015 mg kg‐1 followed by 0.085 mg kg‐1 (divided doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1 (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atracurium 0.075 mg kg‐1 followed by 0.425 mg kg‐1 (divided doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming at 6 min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unpleasant awareness of muscle weakness
Number of subjects: 0
Study: 30381400

Group type: EXPERIMENTAL
Intervention: 60 mg Denosumab (DNM) subcutaneously on day 0 and 180
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 60 mg Denosumab (DNM)
Number of subjects: 63
Study: 27310955

Group type: EXPERIMENTAL
Intervention: Lightweight mesh (LWM)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Heavyweight mesh (HWM)
Number of subjects: 61
Study: 25417309

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D3
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (no 1,25-dihydroxyvitamin D3)
Number of subjects: 44
Study: 23187888

Group type: EXPERIMENTAL
Intervention: Microdose of zidovudine (100 μg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microdose of tenofovir (100 μg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard unlabelled dose of zidovudine (300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard unlabelled dose of tenofovir (300 mg)
Number of subjects: 0
Study: 19834350

Group type: EXPERIMENTAL
Intervention: Low-long exercise condition
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control exercise condition
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: All exercise conditions
Number of subjects: 104
Study: 18690118

Group type: EXPERIMENTAL
Intervention: Nicotine cigarette (0.6 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Denicotinized cigarette (0.05 mg)
Number of subjects: 72
Study: 15842665

Group type: EXPERIMENTAL
Intervention: HiDAC 1 group (ASCT immediately after one course of HiDAC)
Number of subjects: 128

Group type: COMPARATOR
Intervention: HiDAC 2 group (ASCT after one more course of HiDAC)
Number of subjects: 128
Study: 12705643

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (Group II)
Number of subjects: 41

Group type: COMPARATOR
Intervention: On-pump CABG (Group I)
Number of subjects: 41
Study: 10028138

Group type: EXPERIMENTAL
Intervention: Two-state mixed renewal process model for chronic disease activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stratified analyses based on the number of past exacerbations
Number of subjects: 0
Study: 8911222

Group type: EXPERIMENTAL
Intervention: Short-term tryptophan depletion (24-hour low-tryptophan diet followed by an amino acid drink)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham depletion (placebo)
Number of subjects: 20
Study: 1589157

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 3922639

Group type: EXPERIMENTAL
Intervention: HAC (Hexamethylmelamine, adriamycin, and cyclophosphamide)
Number of subjects: 120

Group type: COMPARATOR
Intervention: PAC (cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HAC
Number of subjects: 120

Group type: COMPARATOR
Intervention: PAC
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HAC and PAC
Number of subjects: 120
Study: 30427948

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine, 1 μg/kg over 10 min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (non-jaundiced patients)
Number of subjects: 30
Study: 27119439

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 0
Study: 24677163

Group type: EXPERIMENTAL
Intervention: Perceived discrimination
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Perceived discrimination with stress and depression included
Number of subjects: 1056
Study: 22313605

Group type: EXPERIMENTAL
Intervention: Exposure to fictitious peer's food choices (familiar or unfamiliar)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Fictitious peer influence
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Intervention programmes using peer influence
Number of subjects: 316
Study: 20643014

Group type: EXPERIMENTAL
Intervention: Anterolateral thigh flap
Number of subjects: 19

Group type: COMPARATOR
Intervention: Radial forearm free flap
Number of subjects: 19
Study: 18603344

Group type: EXPERIMENTAL
Intervention: Optimised dentures (intervention)
Number of subjects: 47
Study: 16039333

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 510

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 510
Study: 12442929

Group type: EXPERIMENTAL
Intervention: Intrauterine papaverine (30 mg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.375% 30 mL)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Normal saline (30 mL)
Number of subjects: 66
Study: 11382889

Group type: EXPERIMENTAL
Intervention: Auditory stimulation during sleep
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Experimental nights with auditory arousal threshold studies
Number of subjects: 84

Group type: COMPARATOR
Intervention: Clinical groups vs. respective controls
Number of subjects: 84
Study: 8955676

Group type: EXPERIMENTAL
Intervention: Iodine-123-iodobenzamide (185 MBq, 5 mCi)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 20
Study: 1657017

Group type: EXPERIMENTAL
Intervention: Trazodone (75 mg orally)
Number of subjects: 6
Study: 6360349

Group type: EXPERIMENTAL
Intervention: vincristine (1.4 mg/m2)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: vindesine (3 mg/m2)
Number of subjects: 63
Study: 30769214

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% 20 mL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo 20 mL
Number of subjects: 60
Study: 30149088

Group type: EXPERIMENTAL
Intervention: Trained CPR Coach
Number of subjects: 200
Study: 27060362

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 135

Group type: COMPARATOR
Intervention: Epoetin beta
Number of subjects: 135
Study: 24112799

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 23094720

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 294

Group type: COMPARATOR
Intervention: Class IC or class III antiarrhythmic agents
Number of subjects: 294
Study: 18832432

Group type: EXPERIMENTAL
Intervention: 20 mg citalopram (CIT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 14
Study: 17095239

Group type: EXPERIMENTAL
Intervention: 10ml 0.5% bupivicaine injected to the port sites before incision
Number of subjects: 31

Group type: COMPARATOR
Intervention: 10ml saline
Number of subjects: 31
Study: 15702439

Group type: EXPERIMENTAL
Intervention: Plasma leptin measurement in patients with SAD
Number of subjects: 35

Group type: COMPARATOR
Intervention: Plasma leptin measurement in matched controls
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Assessment of depression severity, appetite scores, and BMI in patients with SAD
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Assessment of body weight changes in subjects with SAD
Number of subjects: 35
Study: 12214580

Group type: EXPERIMENTAL
Intervention: Formoterol fumarate dihydrate (Oxis) at doses of 4.5, 18, and 54 microg via Turbuhaler
Number of subjects: 28

Group type: COMPARATOR
Intervention: Salbutamol at doses of 200 and 1800 microg via pressurised metered dose inhaler (pMDI)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9862585

Group type: EXPERIMENTAL
Intervention: Oral magnesium hydroxide (4.5 g per g elemental iron ingested)
Number of subjects: 13

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 13
Study: 7657902

Group type: EXPERIMENTAL
Intervention: Practice Guidelines Nutrition Care (PGC)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Basic Nutrition Care (BC)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Non-random comparison group (no dietitian contact)
Number of subjects: 179
Study: 2611358

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (CT; combination of sulphamethoxazole 800 mg and trimethoprim 160 mg, twice daily for 5 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (TH alone)
Number of subjects: 8
Study: 976306

Group type: EXPERIMENTAL
Intervention: Flutiorex 20 mg orally
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31673330

Group type: EXPERIMENTAL
Intervention: MoodGYM plus physical treatments
Number of subjects: 108

Group type: COMPARATOR
Intervention: Physical treatments alone
Number of subjects: 108
Study: 29182076

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 26597311

Group type: EXPERIMENTAL
Intervention: 0.50% (6.5mg) DHEA daily for 12 weeks
Number of subjects: 482

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 482
Study: 23636069

Group type: EXPERIMENTAL
Intervention: Early screening with the Gugging Swallowing Screen and intensified oral hygiene
Number of subjects: 146

Group type: COMPARATOR
Intervention: Internal control group (retrospectively selected from same clinic)
Number of subjects: 146

Group type: COMPARATOR
Intervention: External control group (from a comparable stroke unit in a neighboring hospital)
Number of subjects: 146
Study: 21785156

Group type: EXPERIMENTAL
Intervention: Individualised action plan (AP)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 233
Study: 19378685

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Bare metal stent
Number of subjects: 166

Group type: COMPARATOR
Intervention: Late loss
Number of subjects: 166
Study: 17093162

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (400 microg/d)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 15563963

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 66

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 66
Study: 11308044

Group type: EXPERIMENTAL
Intervention: rhIGF-I (40 a.m./40 p.m., 80 a.m./40 p.m., or 80 a.m./60 p.m.)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: rhIGF-I
Number of subjects: 55
Study: 9133551

Group type: EXPERIMENTAL
Intervention: Acetazolamide (1-g i.v.) during hypoglycemia (HYPO-ACZ)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Acetazolamide (1-g i.v.) during euglycemia (EUG-ACZ)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo during hypoglycemia (HYPO-CON)
Number of subjects: 8
Study: 8133793

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (Estraderm TTS, Ciba Geigy; 50 micrograms/day; 24 women)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogens (Premarin, Wyeth; 0.625 mg/day; 20 subjects)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (35 subjects)
Number of subjects: 81
Study: 3298421

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31983626

Group type: EXPERIMENTAL
Intervention: Integration of pharmacists in primary health care teams at 22 sites for approximately 15 months.
Number of subjects: 0
Study: 29392574

Group type: EXPERIMENTAL
Intervention: Single 300-mg dose of droxidopa in the fed state
Number of subjects: 24

Group type: COMPARATOR
Intervention: Single 300-mg dose of droxidopa in the fasted state
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3-times-daily (TID) dosing of droxidopa (three 100-mg capsules at 4-h intervals)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Norepinephrine levels after dose 1 of TID dosing
Number of subjects: 24
Study: 26986171

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (3.7, 4.62, and 5.55 GBq)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (3.7 and 4.62 GBq)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy
Number of subjects: 23
Study: 25425162

Group type: EXPERIMENTAL
Intervention: POCT guided care
Number of subjects: 614

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 614
Study: 24364445

Group type: EXPERIMENTAL
Intervention: Special diet enriched with multicomponent antioxidant foods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 19637993

Group type: EXPERIMENTAL
Intervention: Proactive cardiovascular risk reduction (CaRR) clinic
Number of subjects: 653

Group type: COMPARATOR
Intervention: Nurse telephone calls
Number of subjects: 653

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 653

Group type: COMPARATOR
Intervention: All groups (CaRR, Nurse Phone, Usual Care)
Number of subjects: 653
Study: 17391914

Group type: EXPERIMENTAL
Intervention: Videotape
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Teacher
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Hypothetical mother
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Hypothetical father
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Hypothetical doctor
Number of subjects: 296
Study: 15964061

Group type: EXPERIMENTAL
Intervention: Maintenance haemodialysis (HD)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Maintenance peritoneal dialysis (CAPD)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 61
Study: 12496955

Group type: EXPERIMENTAL
Intervention: Divalproex plus olanzapine
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Divalproex plus risperidone
Number of subjects: 249

Group type: COMPARATOR
Intervention: Olanzapine monotherapy
Number of subjects: 249

Group type: COMPARATOR
Intervention: Risperidone monotherapy
Number of subjects: 249
Study: 11074888

Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy with 5% ethanolamine oleate (median of 5 injections)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy
Number of subjects: 204
Study: 8804075

Group type: EXPERIMENTAL
Intervention: 30 micrograms desmopressin (DDAVP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 60 micrograms desmopressin (DDAVP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1346337

Group type: EXPERIMENTAL
Intervention: Early zidovudine therapy (1500 mg per day)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Late therapy (initially placebo, zidovudine started when CD4+ counts fell below 0.2 x 10(9) per liter or AIDS developed)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Early zidovudine therapy
Number of subjects: 338

Group type: COMPARATOR
Intervention: Late therapy
Number of subjects: 338
Study: 6593675

Group type: EXPERIMENTAL
Intervention: 3 gm of tryptophan in divided 0.5-gm doses over a 24-hour period, beginning before the start of treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo on the same dosage schedule
Number of subjects: 50
Study: 29762903

Group type: EXPERIMENTAL
Intervention: Computer-Assisted Learning (CAL) training sessions
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Musculoskeletal Anatomy training sessions in MA Group
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Cardiovascular Anatomy training sessions in CA Group
Number of subjects: 671
Study: 27885532

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation (0.5 g/kg of ideal body weight)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Hypocaloric diet without whey protein supplementation (Control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 25661800

Group type: EXPERIMENTAL
Intervention: Surgeons' assessment of NRS
Number of subjects: 146

Group type: COMPARATOR
Intervention: Nutritionists' assessment of NRS
Number of subjects: 146
Study: 25422589

Group type: EXPERIMENTAL
Intervention: Yoga training for 1.5 hours per day on 5 consecutive days, followed by daily practice at home for 35-40 minutes and group practice for 2 days a week for 18 weeks.
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group did not participate in yoga program but received intensive yoga training for 5 days after the study.
Number of subjects: 260
Study: 23067910

Group type: EXPERIMENTAL
Intervention: Enhanced depression care intervention (6-month duration, including problem-solving therapy and/or pharmacotherapy)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 157
Study: 19733131

Group type: EXPERIMENTAL
Intervention: Non-invasive liver elastography (Fibroscan)
Number of subjects: 66
Study: 17522584

Group type: EXPERIMENTAL
Intervention: Bbeta15-42 (2.4 mg/kg, n = 6)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (n = 6)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Bbeta15-42 in humans (phase I trial, n = 30)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Random peptide (control; 2.4 mg/kg, n = 6)
Number of subjects: 42
Study: 16225722

Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 40
Study: 12403039

Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 21
Study: 10189324

Group type: EXPERIMENTAL
Intervention: Fish oil concentrate (55% eicosapentaenoic and docosahexaenoic acids) 6 g/d for 3 months and then 3 g/d for 21 months
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo with a fatty acid composition resembling that of the average European diet
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Fish oil concentrate
Number of subjects: 223
Study: 8775636

Group type: EXPERIMENTAL
Intervention: Handsewn anastomosis
Number of subjects: 80

Group type: COMPARATOR
Intervention: Stapled anastomosis
Number of subjects: 80
Study: 2302950

Group type: EXPERIMENTAL
Intervention: Ranitidine plus antacids if necessary to maintain gastric pH at greater than or equal to 4
Number of subjects: 40

Group type: COMPARATOR
Intervention: No drug prophylaxis
Number of subjects: 40
Study: 427041

Group type: EXPERIMENTAL
Intervention: Iron treatment (iron dextran, i.v., total dosage infusion of 30-50 ml)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Iron treatment (iron dextran)
Number of subjects: 16
Study: 30243957

Group type: EXPERIMENTAL
Intervention: Low-dose lipopolysaccharide (LPS, 0.4 ng/kg body weight)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 43
Study: 28393342

Group type: EXPERIMENTAL
Intervention: Oral care program (12 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard post-operative care
Number of subjects: 40
Study: 26449884

Group type: EXPERIMENTAL
Intervention: 100 Hz electroacupuncture (EA) for 15 minutes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (rest for 60 minutes)
Number of subjects: 16
Study: 23359782

Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (cilostazol, clopidogrel, and aspirin)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy (clopidogrel plus aspirin)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Both groups (triple and dual)
Number of subjects: 428
Study: 21328328

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT) with capecitabine (1,650 mg/m²/day)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Postoperative chemoradiotherapy (CRT) with capecitabine (1,650 mg/m²/day)
Number of subjects: 240
Study: 20035644

Group type: EXPERIMENTAL
Intervention: Lidocaine warmed to body temperature (36 degrees Celsius)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lidocaine at room temperature (18 degrees Celsius)
Number of subjects: 80
Study: 17709826

Group type: EXPERIMENTAL
Intervention: Full-field digital mammography (FFDM)
Number of subjects: 23929

Group type: COMPARATOR
Intervention: Screen-film mammography (SFM)
Number of subjects: 23929
Study: 15023706

Group type: EXPERIMENTAL
Intervention: Full disclosure (acceptance of responsibility and an apology)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Full disclosure
Number of subjects: 990

Group type: COMPARATOR
Intervention: Nondisclosure (expression of regret without acceptance of responsibility or an apology)
Number of subjects: 990

Group type: COMPARATOR
Intervention: Nondisclosure
Number of subjects: 990
Study: 11394680

Group type: EXPERIMENTAL
Intervention: Prototype model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exemplar model
Number of subjects: 0
Study: 9710394

Group type: EXPERIMENTAL
Intervention: 1 microg intrathecal sufentanil in 3 ml preservative-free saline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2 microg intrathecal sufentanil in 3 ml preservative-free saline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3 microg intrathecal sufentanil in 3 ml preservative-free saline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5 microg intrathecal sufentanil in 3 ml preservative-free saline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10 microg intrathecal sufentanil in 3 ml preservative-free saline
Number of subjects: 50
Study: 7989940

Group type: EXPERIMENTAL
Intervention: Infusional fluorouracil (I‐FU) 1.2 g/m2/d, as a 72‐hour infusion in the first and third weeks of radiation.
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo (saline infusions).
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Infusional fluorouracil (I‐FU)
Number of subjects: 175
Study: 2644746

Group type: COMPARATOR
Intervention: 1.0 microgram alphacalcidol (1 alpha‐(OH)‐vitamin D3) over 6 months
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 2.0 micrograms alphacalcidol over 1 year
Number of subjects: 31
Study: 7967

Group type: EXPERIMENTAL
Intervention: Sulfentanil (0.05 mg initial dose followed by 0.025 mg repeat injections)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fentanyl (0.5 mg)
Number of subjects: 29